Login / Signup

Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.

Laura A PetrilloAreej R El-JawahriRyan D NippMorgan R L LichtensteinSienna M DurbinKerry Lynn ReynoldsJoseph Andrew GreerJennifer S TemelJustin F Gainor
Published in: Cancer (2020)
Adults with advanced NSCLC and impaired PS experience significantly shorter survival after ICI treatment and receive ICIs near death more often than those with better PS. Receipt of an ICI near death was associated with lower hospice use and an increased risk of death in the hospital. These results underscore the need for high-quality communication about potential tradeoffs of ICIs, particularly among adults receiving ICIs as second-line or later therapy.
Keyphrases
  • small cell lung cancer
  • palliative care
  • stem cells
  • advanced non small cell lung cancer
  • risk assessment
  • bone marrow
  • electronic health record
  • drug induced